Differential effects of two mutations at arginine-234 in the alpha subunit of human pyruvate dehydrogenase.
The most common mutation in the alpha subunit of the pyruvate dehydrogenase (E1) component of the human pyruvate dehydrogenase complex (PDC) is arginine-234 to glycine and glutamine in 12 and 3 patients, respectively. Interestingly, these two mutations at the same amino acid position cause E1 (and hence PDC) deficiency by apparently different mechanisms. Recombinant human R234Q E1 had similar V(max) (25.7 +/- 4.4 units/mg E1) and apparent K(m) (101 +/- 4 nM) values for TPP as recombinant wild-type human E1, while R234G E1 had no significant change in V(max) (33.6 +/- 4.7 units/mg E1) but had a 7-fold increase in its apparent K(m) value for TPP (497 +/- 25 nM). Both of the R234 mutant proteins had similar apparent K(m) values for pyruvate. Both R234Q and R234G mutant proteins displayed similar phosphorylation rates of sites 1 and 2 by pyruvate dehydrogenase kinase 2 (PDK2) and site 3 by PDK1 compared to wild-type E1. Phosphorylated R234Q E1, R234G E1, and wild-type E1 also had similar dephosphorylation rates of sites 1 and 2 by phosphopyruvate dehydrogenase phosphatase 1. The rate of dephosphorylation of site 3 was about 50% for R234Q E1 and without a significant change for R234G E1 compared to the wild type. The data indicate that the patients with the R234G E1 mutation are symptomatic due to a decreased ability of this mutant protein to bind TPP, whereas the patients with the R234Q E1 mutation are symptomatic due to a decreased rate of dephosphorylation of site 3, hence keeping the enzyme in a phosphorylated/inactivated form.
Jacobia
S J
SJ
Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York 14214, USA.
Korotchkina
L G
LG
Patel
M S
MS
D019943:Amino Acid Substitution; D001120:Arginine / Q000235:genetics; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D004795:Enzyme Stability / Q000502:physiology; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011494:Protein Kinases / Q000378:metabolism / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases; D021122:Protein Subunits; D030481:Pyruvate Dehydrogenase (Lipoamide) / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D015325:Pyruvate Dehydrogenase Complex Deficiency Disease / Q000235:genetics*; D013696:Temperature
D007527:Isoenzymes; C000631429:PDK1 protein, human; C000631430:PDK2 protein, human; D021122:Protein Subunits; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D001120:Arginine; D030481:Pyruvate Dehydrogenase (Lipoamide); C065640:pyruvate dehydrogenase E1alpha subunit; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D010744:Phosphoric Monoester Hydrolases